menu
    • menu

    Find Iron Dextran manufacturers, exporters & distributors on PharmaCompass

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    15

    API Suppliers

    API Suppliers

    10

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    1

    EU WC

    EU WC

    0

    KDMF

    KDMF

    1

    NDC API

    NDC API

    5

    VMF

    NDC API

    6

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 206

    MARKET PLACE

    7

    API

    1

    FDF

    0INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    11

    FDF Dossiers

    FDF Dossiers

    0

    FDA Orange Book

    FDA (Orange Book)

    2

    Europe

    Europe

    1

    Canada

    Canada

    0

    Australia

    Australia

    2

    South Africa

    South Africa

    6

    Listed Dossiers

    Listed Dossiers

    0 DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    1

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    NA

    Finished Drug Prices

    NA

    132 RELATED EXCIPIENT COMPANIES

    214EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 9004-66-4, Iron-dextran, Sulfuric acid, iron salt, Iron;sulfuric acid, Fero gradumet, 10124-49-9
    Molecular Formula
    FeH2O4S
    Molecular Weight
    153.93  g/mol
    InChI Key
    MVZXTUSAYBWAAM-UHFFFAOYSA-N
    Iron Dextran
    A complex of ferric oxyhydroxide with dextrans of 5000 to 7000 daltons in a viscous solution containing 50 mg/ml of iron. It is supplied as a parenteral preparation and is used as a hematinic. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1292)
    1 2D Structure

    Iron Dextran

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    iron;sulfuric acid
    2.1.2 InChI
    InChI=1S/Fe.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)
    2.1.3 InChI Key
    MVZXTUSAYBWAAM-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    OS(=O)(=O)O.[Fe]
    2.2 Synonyms
    2.2.1 MeSH Synonyms

    1. Dexferrum

    2. Dextran Iron Complex

    3. Dextran-iron Complex

    4. Dextrofer

    5. Feosol

    6. Ferridextran

    7. Hematran

    8. Icar

    9. Imfergen

    10. Imferon

    11. Imperon

    12. Imposil

    13. Infed

    14. Iron Dextran Complex

    15. Iron-dextran Complex

    16. Norferan

    2.2.2 Depositor-Supplied Synonyms

    1. 9004-66-4

    2. Iron-dextran

    3. Sulfuric Acid, Iron Salt

    4. Iron;sulfuric Acid

    5. Fero Gradumet

    6. 10124-49-9

    7. Sulfuric Acid, Iron(3+) Salt (3:2)

    8. Conferon

    9. Sulfuric Acid Iron Salt (1:1)

    10. Slow-fe

    11. Sulfuric Acid Iron(2+) Salt (1:1)

    12. Sulphuric Acid, Iron Salt

    13. Wln: Fe S-o4

    14. Fe Dextran

    15. Sulfuric Acid, Iron Salt (1:?)

    16. Einecs 233-336-3

    17. Iron Dextran Solution

    18. Sulfuric Acid--iron (1/1)

    19. Dtxsid80906016

    20. Nsc57631

    21. Nsc146177

    22. S6987

    23. Akos030243004

    24. Ft-0624534

    2.3 Create Date
    2005-08-08
    3 Chemical and Physical Properties
    Molecular Weight 153.93 g/mol
    Molecular Formula FeH2O4S
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count4
    Rotatable Bond Count0
    Exact Mass153.902315 g/mol
    Monoisotopic Mass153.902315 g/mol
    Topological Polar Surface Area83 Ų
    Heavy Atom Count6
    Formal Charge0
    Complexity81.3
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Therapeutic Uses

    Hematinics

    National Library of Medicine's Medical Subject Headings. Iron Dextran. Online file (MeSH, 2015). Available from, as of May 1, 2015: https://www.nlm.nih.gov/mesh/2014/mesh_browser/MBrowser.html

    /CLINICAL TRIALS/ ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. The Web site is maintained by the National Library of Medicine (NLM) and the National Institutes of Health (NIH). Each ClinicalTrials.gov record presents summary information about a study protocol and includes the following: Disease or condition; Intervention (for example, the medical product, behavior, or procedure being studied); Title, description, and design of the study; Requirements for participation (eligibility criteria); Locations where the study is being conducted; Contact information for the study locations; and Links to relevant information on other health Web sites, such as NLM's MedlinePlus for patient health information and PubMed for citations and abstracts for scholarly articles in the field of medicine. Iron dextran is included in the database.

    NIH/NLM; ClinicalTrials.Gov. Available from, as of July 18, 2015: https://clinicaltrials.gov/search/intervention=iron+dextran

    Intravenous or intramuscular injections of INFeD are indicated for treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible. /Included in US product labeling/

    NIH; DailyMed. Current Medication Information for INFed (Iron Dextran) Injection (Updated: July 2014). Available from, as of July 21, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abacb7fa-2fc2-471e-9200-944eeac8ca2a

    MEDICATION (VET): Nutritional factor (parenteral). Used in iron deficiency anemia, chiefly in pigs.

    O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK: Royal Society of Chemistry, 2013., p. 948

    For more Therapeutic Uses (Complete) data for IRON DEXTRAN (8 total), please visit the HSDB record page.

    4.2 Drug Warning

    /BOXED WARNING/ WARNING: RISK FOR ANAPHYLACTIC-TYPE REACTIONS. Anaphylactic-type reactions, including fatalities, have followed the parenteral administration of iron dextran injection. Have resuscitation equipment and personnel trained in the detection and treatment of anaphylactic-type reactions readily available during INFeD administration. Administer a test INFeD dose prior to the first therapeutic dose. If no signs or symptoms of anaphylactic-type reactions follow the test dose, administer the full therapeutic INFeD dose. During all INFeD administrations, observe for signs or symptoms of anaphylactic-type reactions. Fatal reactions have followed the test dose of iron dextran injection. Fatal reactions have also occurred in situations where the test dose was tolerated. Use INFeD only in patients in whom clinical and laboratory investigations have established an iron deficient state not amenable to oral iron therapy. Patients with a history of drug allergy or multiple drug allergies may be at increased risk of anaphylactic-type reactions to INFeD.

    NIH; DailyMed. Current Medication Information for INFed (Iron Dextran) Injection (Updated: July 2014). Available from, as of July 21, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abacb7fa-2fc2-471e-9200-944eeac8ca2a

    Abdominal pain, dyspepsia, nausea, vomiting, diarrhea, metallic taste in the mouth, altered taste, and transient loss of taste perception have occurred in patients receiving iron dextran.

    American Society of Health-System Pharmacists 2015; Drug Information 2015. Bethesda, MD. 2015, p. 1447

    Anaphylactic or anaphylactoid reactions to iron dextran, including fatal anaphylaxis, have been reported. These reactions occur most frequently within the first several minutes of administration and are generally characterized by sudden onset of respiratory difficulty (e.g., wheezing, bronchospasm, rigor, dyspnea, cyanosis), tachycardia, hypotension, respiratory arrest, and/or cardiovascular collapse. The manufacturers state that concomitant use of angiotensin-converting enzyme (ACE) inhibitors may increase the risk for reactions to iron dextran. The level of risk for anaphylactic-type reactions following exposure to specific iron dextran preparations is not known and may vary. Iron dextran preparations differ in chemical characteristics and may differ in clinical effects; the manufacturers state that such preparations are not clinically interchangeable. Acute hypersensitivity reactions to iron dextran have been estimated to occur in 0.2-3% of patients. These reactions have been reported after administration of uneventful test doses of iron dextran as well as after therapeutic doses of the drug. Although it has been suggested that severe systemic reactions, including anaphylactoid reactions, are more common following IV rather than IM administration of iron dextran, the risk of severe systemic reactions following IV or IM administration has not been directly compared and there appears to be no well-substantiated evidence of a difference in the frequency of anaphylactoid reactions following either route of administration.

    American Society of Health-System Pharmacists 2015; Drug Information 2015. Bethesda, MD. 2015, p. 1447

    Large IV doses of iron dextran, such as those used in total-dose infusions, may be associated with an increased frequency of adverse effects, especially delayed (1-2 days) reactions manifested by arthralgia, backache, myalgia, adenopathy, moderate to high fever, backache, chills, dizziness, headache, malaise, nausea, and/or vomiting. The onset of these adverse effects is usually 24-48 hours after administration of the drug, and the effects generally subside within 3-4 days. Delayed adverse effects have also occurred following IM administration and usually subsided within 3-7 days. The etiology of delayed adverse effects is not known, but the symptom complex resembles that of a serum sickness reaction. Patients with rheumatoid arthritis and possibly other inflammatory diseases (e.g., ankylosing spondylitis, lupus erythematosus) may be at particular risk for delayed reactions. IV administration of iron dextran has caused fever and exacerbation or reactivation of joint pain and swelling in patients with rheumatoid arthritis; in addition, exacerbation of ankylosing spondylitis in one patient and arthralgia, myalgia, erythema nodosum, and fever in a patient with lupus erythematosus have been reported. Such exacerbations of underlying inflammatory conditions may respond to nonsteroidal anti-inflammatory agent (NSAIA) therapy and may be prevented with corticosteroid pretreatment.

    American Society of Health-System Pharmacists 2015; Drug Information 2015. Bethesda, MD. 2015, p. 1447

    For more Drug Warnings (Complete) data for IRON DEXTRAN (21 total), please visit the HSDB record page.

    4.3 Drug Indication

    For treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible. Also used to replenish body iron stores in Non-Dialysis Dependent-Chronic Kidney Disease (NDD-CKD) patients receiving or not receiving erythropoietin and in Hemodialysis Dependent (HDD-CKD) and Peritoneal Dialysis Dependent (PDD-CKD) - Chronic Kidney Disease patients receiving an erythropoietin.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Iron dextran is a dark brown, slightly viscous sterile liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. It is for treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible. Iron is essential to the formation of hemoglobin and to the function and formation of other heme and nonheme compounds. Untreated depletion of iron stores leads to iron-deficient erythropoiesis and, in turn, to iron deficiency anemia.

    5.2 MeSH Pharmacological Classification

    Hematinics

    Agents which improve the quality of the blood, increasing the hemoglobin level and the number of erythrocytes. They are used in the treatment of anemias. (See all compounds classified as Hematinics.)

    5.3 FDA Pharmacological Classification
    5.3.1 Pharmacological Classes
    Parenteral Iron Replacement [EPC]; Phosphate Binder [EPC]; Phosphate Chelating Activity [MoA]; Iron [CS]
    5.4 Absorption, Distribution and Excretion

    Absorption

    The major portion of intramuscular injections of iron dextran is absorbed within 72 hours; most of the remaining iron is absorbed over the ensuing 3 to 4 weeks.

    Route of Elimination

    Dextran, a polyglucose, is either metabolized or excreted.

    Following intramuscular administration, iron dextran is absorbed from the site of injection primarily through the lymphatic system. Absorption takes place in two stages. Approximately 60% of the dose or iron dextran inected is absorbed within 72 hours of administration. Ninety percent of the dose is absorbed in the second, slower, phase lasting approximately 1 to 3 weeks in duration. The remaining 10% of the dose is gradually absorbed over a period of several months or longer.

    Health Canada; Product Monograph for Dexiron (Iron Dextran Injection, USP (50 mg Elemental Iron/mL) 1 mL, 2 ml Single-Dose Vials), Drug Identification Number (DIN): 02205963 p.16 (Date of Revision: January 2, 2013). Available from, as of July 21, 2015: https://webprod5.hc-sc.gc.ca/dpd-bdpp/start-debuter.do?lang=eng

    Following IM or IV injection, iron dextran is gradually cleared from plasma by reticuloendothelial cells of liver, spleen, and bone marrow. Results of several studies indicate that /a/ variable portion of IV dose... may be stored in unusable form in bone marrow.

    American Society of Health-System Pharmacists 2015; Drug Information 2015. Bethesda, MD. 2015, p. 1448

    In vitro studies have shown that removal of iron dextran by dialysis is negligible.

    NIH; DailyMed. Current Medication Information for INFed (Iron Dextran) Injection (Updated: July 2014).

    /MILK/ Traces of unmetabolized iron dextran are excreted in human milk.

    NIH; DailyMed. Current Medication Information for INFed (Iron Dextran) Injection (Updated: July 2014). Available from, as of July 21, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abacb7fa-2fc2-471e-9200-944eeac8ca2a

    For more Absorption, Distribution and Excretion (Complete) data for IRON DEXTRAN (6 total), please visit the HSDB record page.

    5.5 Metabolism/Metabolites

    Dextran, a polyglucose, is either metabolized or excreted.

    Dextran, a polyglucose, is either metabolized or excreted. Only traces of unmetabolized iron dextran are excreted in the urine, bile or feces.

    American Society of Health-System Pharmacists 2015; Drug Information 2015. Bethesda, MD. 2015, p. 1448

    5.6 Biological Half-Life

    5 hours (some indications that it can be as long as 10 hours)

    After intravenous injection of 2 mL of DexIron (100 mg iron) to renal dialysis patients ... the average half-life of iron dextran in serum was 58.9 hours, ranging from 9.4 to 87.4 hours in 20 patients.

    Health Canada; Product Monograph for Dexiron (Iron Dextran Injection, USP (50 mg Elemental Iron/mL) 1 mL, 2 ml Single-Dose Vials), Drug Identification Number (DIN): 02205963 p.16 (Date of Revision: January 2, 2013). Available from, as of July 21, 2015: https://webprod5.hc-sc.gc.ca/dpd-bdpp/start-debuter.do?lang=eng

    Various studies involving intravenously administered (59)Fe iron dextran to iron deficient subjects, some of whom had coexisting diseases, have yielded half-life values ranging from 5 hours to more than 20 hours. The 5-hour value was determined for (59)Fe iron dextran from a study that used laboratory methods to separate the circulating (59)Fe iron dextran from the transferrin-bound (59)Fe. The 20-hour value reflects a half-life determined by measuring total (59)Fe, both circulating and bound. It should be understood that these half-life values do not represent clearance of iron from the body. Iron is not easily eliminated from the body and accumulation of iron can be toxic.

    NIH; DailyMed. Current Medication Information for INFed (Iron Dextran) Injection (Updated: July 2014). Available from, as of July 21, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abacb7fa-2fc2-471e-9200-944eeac8ca2a

    5.7 Mechanism of Action

    After iron dextran is injected, the circulating iron dextran is removed from the plasma by cells of the reticuloendothelial system, which split the complex into its components of iron and dextran. The iron is immediately bound to the available protein moieties to form hemosiderin or ferritin, the physiological forms of iron, or to a lesser extent to transferrin. This iron which is subject to physiological control replenishes hemoglobin and depleted iron stores.

    ... Circulating iron dextran is removed from the plasma by cells of the reticuloendothelial system, which split the complex into its components of iron and dextran. The iron is immediately bound to the available protein moieties to form hemosiderin or ferritin, the physiological forms of iron, or to a lesser extent to transferrin. This iron which is subject to physiological control replenishes hemoglobin and depleted iron stores.

    NIH; DailyMed. Current Medication Information for INFed (Iron Dextran) Injection (Updated: July 2014).

    ... The toxicity of iron in biological systems is believed to be attributed to its ability to catalyze the generation of oxygen-free radicals. In the current investigation, the dose-dependent effects of chronic iron-loading on heart tissue concentrations of iron, glutathione peroxidase (GPx) activity, free-radical production, and cardiac dysfunction were investigated in a murine model of iron-overload cardiomyopathy. It was shown that chronic iron-overload results in dose-dependent (a) increases in myocardial iron burden, (b) decreases in the protective antioxidant enzyme GPx activity, (c) increased free-radical production, and (d) increased mortality. These findings show that the mechanism of iron-induced heart dysfunction involves in part free radical-mediated processes.

    PMID:11232511 Bartfay WJ, Bartfay E; Biol Res Nurs 2 (1): 49-59 (2000)

    API SUPPLIERS

    read-more
    read-more
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1629052200,"product":"IRON DEXTRAN POWER","address":"114 MARINE CHAMBERS ,11 NEW MARINE LINES ,MUMBAI,","city":"MAHARASHTRA","supplier":"SWATI SPENTOSE","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO","customer":"TO ORDER.","customerCountry":"RUSSIA","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"285","totalValueFC":"835.9","currency":"USD","unitRateINR":20666.666666666668,"date":"16-Aug-2021","totalValueINR":"62000","totalValueInUsd":"835.9","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"3879965","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"114 MARINE CHAMBERS ,11 NEW MARINE LINES ,MUMBAI,, MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1633631400,"product":"IRON DEXTRAN POWDER","address":"114 MARINE CHAMBERS ,11 NEW MARINE LINES ,MUMBAI,","city":"MAHARASHTRA","supplier":"SWATI SPENTOSE","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO","customer":"TO ORDER.","customerCountry":"RUSSIA","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"250","totalValueFC":"520.6","currency":"USD","unitRateINR":13000,"date":"08-Oct-2021","totalValueINR":"39000","totalValueInUsd":"520.6","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"5163591","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"114 MARINE CHAMBERS ,11 NEW MARINE LINES ,MUMBAI,, MAHARASHTRA","customerAddress":""}]
    16-Aug-2021
    08-Oct-2021
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Granulation

    read-more
    read-more

    Topical

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Market Place

    Do you need sourcing support? Ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search